- Gelsemine
-
- $47.00 / 5mg
-
2024-11-19
- CAS:509-15-9
- Min. Order:
- Purity: 99.81%
- Supply Ability: 10g
- Gelsemine
-
- $0.00 / 20mg
-
2023-02-24
- CAS:509-15-9
- Min. Order: 20mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- GELSEMINE
-
- $15.00 / 1KG
-
2021-07-02
- CAS:509-15-9
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | GELSEMINE Basic information |
| Product Name: | GELSEMINE | | Synonyms: | (3r-(3alpha,4abeta,5alpha,8alpha,8abeta,9s*,10s*))-5-ethenyl-3,4,4a,5,6,7,8,8a;[3R-(3alpha,4abeta,5alpha,8alpha,8abeta,9S*,10S*)]-5-Etheny l-3,4,4a,5,6,7,8,8a-octahydro-7-methylspiro[3,5,8-ethanylylidene-1H-p yrano[3,4-c]pyridine-10,3'-[3H]indol]-2'(1'H)-one;3h)indol)-2’(1’,h)-one;8abeta,9s*,10s*))-8alph;Gelsemin;ne,5-ethenyl-3,4,4a,5,6,7,8,8a-octahydro-7-methyl-,(3r-(3alpha,4abeta,5alpha,;-octahydro-7-methylspiro(3,5,8-ethanylylidene-1h-pyrano(3,4-c)pyridine-10,3’-(;spiro(3,5,8-ethanylylidene-1h-pyrano(3,4-c)pyridine-10,3’-(3h)indol)-2’(1’h)-o | | CAS: | 509-15-9 | | MF: | C20H22N2O2 | | MW: | 322.4 | | EINECS: | 208-095-2 | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Alkaloids | | Mol File: | 509-15-9.mol |  |
| | GELSEMINE Chemical Properties |
| Melting point | 181-183°C | | alpha | D20 +13° (c = 1.2 in chloroform) | | Boiling point | 461.02°C (rough estimate) | | density | 1.1478 (rough estimate) | | refractive index | 1.5700 (estimate) | | storage temp. | 2-8°C | | solubility | Chloroform (Slightly), Methanol (Slightly) | | pka | 7.75 in 80% methylcellosolve | | form | powder | | color | White | | LogP | 3.080 (est) |
| | GELSEMINE Usage And Synthesis |
| Uses | Medicine, as a CNS stimulant | | Hazard | A toxic plant alkaloid | | in vivo | Gelsemine is an effective agent for treatment of both neuropathic pain and sleep disturbance in partial sciatic nerve ligation (PSNL) mice. Gelsemine (4 mg/kg) exerts analgesic effects on PSNL-induced mechanical allodynia and thermal hyperalgesia. In PSNL mice, Gelsemine (2 and 4 mg/kg) increases the mechanical threshold for 4 h and prolonged the thermal latencies for 3 h. Furthermore, Gelsemine (4 mg/kg, administered at 6:30 AM) increases non-rapid eye movement (non-REM, NREM) sleep, decreases wakefulness, but does not affect rapid eye movement (REM) sleep during the first 3 h in PSNL mice[1].
Immunohistochemical study shows that PSNL increases c-Fos expression in the neurons of the anterior cingulate cortex, and Gelsemine (4 mg/kg) decreases c-Fos expression by 58%[1]. |
| | GELSEMINE Preparation Products And Raw materials |
|